AVBP stock icon

ArriVent BioPharma
AVBP

$19.65
0.86%

Market Cap: 658M

 

About: ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Employees: 40

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

38,889,087,200% more capital invested

Capital invested by funds: $0 [Q4 2023] → $389M (+$389M) [Q1 2024]

5,300% more funds holding

Funds holding: 0 [Q4 2023] → 53 (+53) [Q1 2024]

5,300% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 0

400% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 4 (+4) [Q1 2024]

68.37% more ownership

Funds ownership: 0% [Q4 2023] → 68.37% (+68.37%) [Q1 2024]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$25
27%
upside
Avg. target
$28
42%
upside
High target
$35
78%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
27%upside
$25
Buy
Reiterated
6 Jun 2024
HC Wainwright & Co.
Robert Burns
27%upside
$25
Buy
Reiterated
9 May 2024
HC Wainwright & Co.
Robert Burns
27%upside
$25
Buy
Initiated
30 Apr 2024
Citigroup
Yigal Nochomovitz
53%upside
$30
Buy
Initiated
20 Feb 2024
Jefferies
Kelly Shi
78%upside
$35
Buy
Initiated
20 Feb 2024

Financial journalist opinion